Analysts expect Acceleron Pharma Inc. (NASDAQ:XLRN) to post earnings of ($0.61) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Acceleron Pharma’s earnings. The highest EPS estimate is ($0.57) and the lowest is ($0.68). Acceleron Pharma posted earnings of ($0.51) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 19.6%. The firm is expected to announce its next quarterly earnings report on Wednesday, March 7th.

On average, analysts expect that Acceleron Pharma will report full-year earnings of ($2.67) per share for the current financial year, with EPS estimates ranging from ($2.76) to ($2.60). For the next fiscal year, analysts forecast that the business will post earnings of ($2.41) per share, with EPS estimates ranging from ($2.61) to ($2.19). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Acceleron Pharma.

Acceleron Pharma (NASDAQ:XLRN) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.67) by $0.02. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The firm had revenue of $3.00 million for the quarter, compared to analyst estimates of $3.52 million. During the same quarter last year, the company earned ($0.55) EPS. The company’s revenue was up .0% on a year-over-year basis.

XLRN has been the topic of a number of research analyst reports. Credit Suisse Group set a $51.00 target price on Acceleron Pharma and gave the company a “buy” rating in a report on Tuesday, November 14th. HC Wainwright initiated coverage on Acceleron Pharma in a report on Thursday, October 12th. They issued a “buy” rating and a $57.00 target price on the stock. Barclays raised their target price on Acceleron Pharma from $42.00 to $50.00 and gave the company an “overweight” rating in a report on Wednesday, September 20th. ValuEngine raised Acceleron Pharma from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Finally, Royal Bank Of Canada reaffirmed a “hold” rating on shares of Acceleron Pharma in a report on Thursday, November 2nd. Two research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $44.88.

Acceleron Pharma (NASDAQ XLRN) traded up $1.60 during trading on Friday, reaching $36.49. The company’s stock had a trading volume of 310,800 shares, compared to its average volume of 386,013. Acceleron Pharma has a 12-month low of $23.07 and a 12-month high of $40.35.

In other Acceleron Pharma news, major shareholder Corp /De/ Celgene acquired 745,592 shares of the stock in a transaction dated Monday, September 25th. The stock was purchased at an average cost of $37.00 per share, with a total value of $27,586,904.00. Following the transaction, the insider now owns 6,118,479 shares in the company, valued at approximately $226,383,723. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, CFO Kevin F. Mclaughlin sold 16,000 shares of Acceleron Pharma stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $38.41, for a total value of $614,560.00. Following the completion of the transaction, the chief financial officer now directly owns 50,810 shares of the company’s stock, valued at $1,951,612.10. The disclosure for this sale can be found here. Insiders have sold a total of 53,513 shares of company stock worth $2,055,485 over the last ninety days. Company insiders own 3.90% of the company’s stock.

A number of institutional investors have recently modified their holdings of XLRN. Parametric Portfolio Associates LLC bought a new stake in Acceleron Pharma in the 1st quarter valued at about $241,000. Teachers Advisors LLC increased its position in Acceleron Pharma by 2.1% in the 1st quarter. Teachers Advisors LLC now owns 46,080 shares of the biopharmaceutical company’s stock valued at $1,220,000 after buying an additional 942 shares in the last quarter. Vanguard Group Inc. increased its position in Acceleron Pharma by 9.1% in the 1st quarter. Vanguard Group Inc. now owns 1,912,335 shares of the biopharmaceutical company’s stock valued at $50,619,000 after buying an additional 158,714 shares in the last quarter. Geode Capital Management LLC increased its holdings in Acceleron Pharma by 2.8% during the 1st quarter. Geode Capital Management LLC now owns 271,440 shares of the biopharmaceutical company’s stock worth $7,185,000 after purchasing an additional 7,378 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. increased its holdings in Acceleron Pharma by 5.9% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 131,841 shares of the biopharmaceutical company’s stock worth $3,490,000 after purchasing an additional 7,335 shares in the last quarter. 85.73% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/01/zacks-brokerages-anticipate-acceleron-pharma-inc-xlrn-to-post-0-61-earnings-per-share.html.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Get a free copy of the Zacks research report on Acceleron Pharma (XLRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.